A case of delayed oxaliplatin-induced pseudo-obstruction: An atypical presentation of oxaliplatin neurotoxicity

Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine

Volumn 70, Issue 3, 2015, Pages 207-210

  Vandamme, M ^a,b   Pauwels, W ^b   De Bleecker, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Algemeen Ziekenhuis Sint Lucas Gent   (Belgium)

Author keywords

Autonomic neuropathy; Metastatic colorectal cancer; Neurotoxicity; Oxaliplatin; Pseudo obstruction

Indexed keywords

DIURETIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROKINETIC AGENT; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ACUTE ABDOMEN; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ANOREXIA; ARTICLE; AUTONOMIC NEUROPATHY; CANCER SIZE; CANCER STAGING; CASE REPORT; CHOLECYSTECTOMY; COLON DILATATION; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HEMICOLECTOMY; HUMAN; INTESTINE PSEUDOOBSTRUCTION; LIVER RESECTION; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PARESTHESIA; POSTOPERATIVE PERIOD; PSEUDOOBSTRUCTION; SENSORY AXONAL NEUROPATHY; SIDE EFFECT; TOTAL PARENTERAL NUTRITION; WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION; ADENOCARCINOMA; CHEMICALLY INDUCED; COLON RESECTION; COLONIC PSEUDO-OBSTRUCTION; COLORECTAL NEOPLASMS; COMPLICATION; LIVER NEOPLASMS; NEUROTOXICITY SYNDROMES; PARENTERAL NUTRITION; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COLONIC PSEUDO-OBSTRUCTION; COLORECTAL NEOPLASMS; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PARENTERAL NUTRITION; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 84942598163     PISSN: 17843286     EISSN: 22953337     Source Type: Journal    
DOI: 10.1179/2295333714Y.0000000110     Document Type: Article

References (7)

1. Wafai L, Taher M, Jovanovska V., Bornstein JC, Dass CR, Nurgali K. Effects of oxaliplatin on mouse myenteric neurons and colonic motility. Front Neurosci. 2013; 7:30.
2. Xiao WH, Zheng H, Bennett GJ Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison to the neuropathy induced by paclitaxel. Neuroscience. 2012; 203:194-206.
3. Vera G, Castillo M, Cabezos P.A., Chiarlone A., Martin MI, Gori A, et al. Enteric neuropathy evoked by repeated cisplatin in the rat. Neurogastroenterol Motil. 2011; 23:370-8.
4. Benarroch EE, Daube JR, Flemming K.D., Westmoreland BF. Chapter 9: The internal regulation system. In: Benarroch EE, Daube JR, Flemming KD, Westmoreland BF, editors. Mayo clinic medical neurosciences: organized by neurologic systems and levels. 5th ed. Oxford: Mayo Clinic Scientific Press; 2008. p. 379-80.
5. Argyriou AA, Polychronopoulos P, Iconomou G., Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008; 34(4): 368-77.
6. Taieb S, Trillet-Lenoir V, Rambaud L., Descos L, Freyer G. Lhermitte sign and urinary retention, atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002; 94: 2434-40.
7. Windebank AJ. Diseases of the peripheral nervous system: metal neuropathy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy. 4th ed. Vol. 2. Philadelphia, PA: Elsevier; 2005. p. 2544-5.